Finn Patrick John, an officer at Twist Bioscience Corp, has filed a Form 144 indicating the sale of 2,565 shares of common stock. The shares, valued at approximately $347,305.36, were sold on November 3, 2026. This transaction is significant as it showcases the ongoing activity of executives in the biological products industry, particularly following the vesting of stock options.

Twist Bioscience Corp, incorporated in Delaware, operates in the biological products sector. The company, which trades on the NASDAQ under the ticker symbol TWST, is focused on synthetic DNA production and related technologies. Recent filings indicate that the company is actively managing its stock and compliance with SEC regulations, as evidenced by the multiple transactions reported in recent weeks.

The SEC filing reveals that John acquired the shares through a restricted stock vesting transaction dated November 2, 2026. The filing notes that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.

This sale may impact the company's stock performance and investor perceptions, as insider transactions can often signal confidence or concerns about a company's future. The filing also highlights the role of Fidelity Brokerage Services LLC in facilitating the transaction.

Looking ahead, further filings from Twist Bioscience or additional disclosures from John may provide more insight into future stock transactions or company performance. The filing does not specify what happens next.